Literature DB >> 26542634

Tumour immunology: Reducing silence to improve therapy.

Elisabeth Kugelberg.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26542634     DOI： 10.1038/nri3941

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  1 in total

1.  Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Authors:  Dongjun Peng; Ilona Kryczek; Nisha Nagarsheth; Lili Zhao; Shuang Wei; Weimin Wang; Yuqing Sun; Ende Zhao; Linda Vatan; Wojciech Szeliga; Jan Kotarski; Rafał Tarkowski; Yali Dou; Kathleen Cho; Sharon Hensley-Alford; Adnan Munkarah; Rebecca Liu; Weiping Zou
Journal:  Nature       Date:  2015-10-26       Impact factor: 49.962
  1 in total
  2 in total

1.  Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.

Authors:  Liye Zhou; Tenny Mudianto; Xiaojing Ma; Rachel Riley; Ravindra Uppaluri
Journal:  Clin Cancer Res       Date:  2019-09-27       Impact factor: 12.531

2.  EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.

Authors:  Baoping Guo; Xiaohong Tan; Hong Cen
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.